Tiffany Sia, MD, on Procedural Interventions for Gynecologic Malignancies With Oligoprogressive Disease During ICI

Video
Conference|Annual Global Meeting of the International Gynecologic Cancer Society

Tiffany Sia, MD, spoke about major takeaways from her study and how to implement procedural interventions for patients with gynecologic malignancies who have oligoprogression.

CancerNetwork® spoke with Tiffany Sia, MD, a gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center in New York, during the 2022 Annual Global Meeting of the International Gynecologic Cancer Society about different procedural interventions used across 887 patients with gynecologic malignancies who experienced oligoprogression during treatment with immune checkpoint inhibitors (ICI) at her institution. In a chart review, interventions included either surgical resection (n = 10), interval radiation (IR) ablation (n = 3), or radiation therapy (n = 28) in 41 total patients who received ICI and had oligoprogressive disease. These types of interventions appeared to benefit this patient subset and offers evidence for working them into treatment for better survival outcomes.

Transcript:

What we found is that the patients who were treated with either surgical procedures, radiation therapies, or IR-guided ablations had very favorable outcomes overall. We would recommend that we can continue to treat these patients with oligoprogression with combined modalities of immune checkpoint blockade and consider these procedural interventions for localized oligoprogression.

The take-home point is that this is feasible and the patients overall have good outcomes. We should not rule out the possibility of an interventional procedure just because a patient is on immune checkpoint blockade; it is doable. This is an ongoing field of study. The number of patients in our cohort is relatively small, but as more and more patients being treated with these types of drugs and seeing responses, we might have more patients with oligoprogression. This is going to be an interesting question moving forward.

Reference

Sia T, Wan V, Zivanovec O, et al. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies. Presented at the Annual Global Meeting of the International Gynecologic Cancer Society; New York, NY; September 29-October 1, 2022. Poster FP014.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Related Content
Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Rintatolimod Combo Yields Clinical Benefit in Recurrent Ovarian Cancer

April 11th 2024
Article

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Avutometinib Combo Yields Responses in Serous Ovarian Cancer Subgroups

March 26th 2024
Article

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer

March 19th 2024
Article

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Frontline Durvalumab Combo Improves PFS/DOR in Advanced Endometrial Cancer

March 19th 2024
Article

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.